Drug recall · January 15, 2020
Ranitidine 150 mg tablets recall
Why: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04.
- Lots / codes
P134457, Sept 2020 P135156, Aug 2020 P135156, Aug 2020 P135243, Aug 2020 P135877, Sept 2020 P136145, Aug 2020 P136146, Sept 2020 P136623, April 2021 P136728, April, 2021 P136994, April, 2021 P137348, April, 2021 P137423, April, 2021 P137499, April, 2021
- Quantity
- 31,536 (130-count bottles)
- Company
- AAA Pharmaceutical, Inc., Lumberton, NJ
- Distribution
- Product was distributed to one consignee who may have distributed the product further to their retail stores.
- Initiated
- December 26, 2019 · Voluntary: Firm initiated
- Classified
- January 6, 2020
- Reported
- January 15, 2020
- Ended
- March 10, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.